Roche Holding AG (SWX:RO)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 299.06B +40.4% |
| Revenue (ttm) | 63.36B +1.5% |
| Net Income | 12.88B +55.6% |
| EPS | n/a |
| Shares Out | n/a |
| PE Ratio | 23.22 |
| Forward PE | 18.44 |
| Dividend | 9.70 (2.72%) |
| Ex-Dividend Date | Mar 27, 2025 |
| Volume | 35,829 |
| Average Volume | 21,903 |
| Open | 352.40 |
| Previous Close | 352.60 |
| Day's Range | 351.00 - 358.20 |
| 52-Week Range | 244.00 - 362.80 |
| Beta | 0.17 |
| RSI | 61.15 |
| Earnings Date | Jan 29, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial StatementsNews
Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance
From a sector perspective, strength within Industrials and Information Technology offset relative weakness in Health Care. The October earnings report reinforced confidence in Comfort Systems' ability...
Roche Holding AG (RHHBY) Q4 2025 Earnings Call Transcript
Roche Holding AG (RHHBY) Q4 2025 Earnings Call Transcript
Roche's Full-Year Earnings: Solid, No Alarms - Obesity Promise Makes The Buy Case
Hoffman-La Roche aka Roche Holding AG delivered robust 2025 results, with core EPS up 11% CER and a resilient pharma division driving growth. RHHBY's pipeline, especially in obesity and cardiovascular...
Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite
Drugmakers Roche and Sanofi posted full-year earnings that matched expectations and did little to move either stock. As pharma companies face a "patent cliff" where existing drugs lose exclusivity, th...
Roche Forecasts 2026 Growth, Helped by Strength of Drug Pipeline
The Swiss drugmaker said it expects sales to grow in the mid-single-digit range, with core EPS growth in the high-single-digit range at constant currencies.
Roche sees high single-digit earnings growth in 2026
Roche ROG.S said on Thursday it expects 2026 group sales to grow in the mid single-digit percentage range, while targeting core earnings per share growth in the high single-digit range.
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth
Outlook for 2026 Roche (SIX: RO, ROG; OTCQX: RHHBY) expects an increase in Group sales in the mid single digit range (CER) for 2026. Core earnings per share are targeted to develop in the high single ...
Roche's CT-388 Adds Optionality In The GLP Market, But Wait For Dips
Roche Is The 'Value Play' Of The 2026 Obesity Gold Rush
Roche: Important De-Risking Of CT-388 In Obesity, Petrelintide Is Next
Roche's (RHHBY) CT-388 Shows Promising Weight Loss Results in Phase 2 Trial
Roche's (RHHBY) CT-388 Shows Promising Weight Loss Results in Phase 2 Trial
Roche Shares Rise After Obesity Drug Shows 18% Greater Weight Loss
Roche Shares Rise After Obesity Drug Shows 18% Greater Weight Loss
Roche's Obesity Drug Helps Almost 87% People Lose At Least 10% Weight
Roche released Phase 2 trial results showing its weekly obesity drug CT-388 helped patients lose up to 22.5% body weight with strong tolerability and no weight loss plateau at 48 ... Full story availa...
Genentech's CT388 Demonstrates Significant 22.5% Weight Loss In Phase 2 Study
(RTTNews) - Genentech, a biotechnology firm and member of the Roche Group (RHHBY,ROG.SW), announced positive topline results from its Phase 2 clinical trial of CT-388 in obesity.
Roche Says Weight-Loss Shot Achieved Positive Results in Midstage Trial
A late-stage trial program of CT-388 is expected to start this quarter.
Roche: Phase II Trial Of CT-388 Achieves Statistically Significant Placebo-adjusted Weight Loss
(RTTNews) - Roche (RO.SW, ROG.SW) reported positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP receptor agonist being developed for the trea...
Roche announces positive phase II results for dual GLP-1/GIP receptor
Swiss pharmaceutical firm Roche said on Tuesday that a phase II clinical trial of CT-388, an investigational dual GLP-1/GIP receptor being developed to treat obesity, delivered positive results.
Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from CT388-103, a Phase II clinical trial of...
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity
Basel, 27 January 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP receptor ago...
Gold headed to $6,000 - Veteran investor tells us why
David Roche from Quantum Strategy shared his outlook on markets amid geopolitical tensions, forecasting Japan’s 10-year government bond yield to rise to 2.9% within a year as government debt increases...
Roche (RHHBY) Expands Investment in North Carolina Facility
Roche (RHHBY) Expands Investment in North Carolina Facility
Roche more than doubles investment in new North Carolina site
Genentech To Create Additional 100 Jobs With Further Investment In North Carolina Facility
(RTTNews) - Biotechnology company Genentech, a subsidiary of Roche Holding AG (RHHBY.PK), Tuesday announced an expansion of its initial investment in a new Holly Springs, North Carolina manufacturing ...
Roche's Genentech more than doubles investment in North Carolina facility to about $2 billion
Roche's Genentech said on Tuesday it will more than double its initial investment in a biomanufacturing facility in North Carolina to about $2 billion, as the companies look to further boost their $50...
Genentech More than Doubles Investment in Holly Springs, North Carolina Manufacturing Facility
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced an expansion of its initial investment in a new Holly Springs, North ...